Resources Clinical studies Patient Profile Synjardy 1 2 3 Infographics SYNJARDY a twice daily oral medication that should be taken with meals. SYNJARDY helps you do more for patients like Abdullah by reducing their risk of CV death. Diabetes magazine V1 49.5 mmHg SBP reduction 80 % goal achieved with Twynsta ONTARGET program: Study Design Telmisartan Attributes Telmisartan Therapeutic indications A classic ARB-HCTZ CHOICE for elderly patients Early intervention FUE infographic GOLD 2019 Addressing all COPD endpoints New Exacerbation data Otivacto real world evidence perspective VIVACITO Infographic VESUTO Infographic IRE Spiolto Tonado Trial Summary PHYSACTO Infographic OTIVATO Infographic Energito Clinical Review Thierry Troosters AJRCCM Articles in Press The Effect of Tiotropium.Olodaterol Versus Tiotropium Masakazu Ichinose International Journal of COPD Kai-Michael Beeh Pulmonary Pharmacology & Therapeutics Kai-Michael Beeh Pulmonary Francois Maltais Boehringer Ingelhiem Fabienne Dobbels ORIGINAL ARTICLE REHABILITATION Recommended dose & administration method for Actilyse Actilyse Treatment Increases the Chance of a Favourable Outcome for Acute Stroke Patient Post Call - Benefits of Earlier Treatment with Actilyse for Stroke Patient How should you perform the F.A.S.T. Test? Dosing & Administering Metalyse Management of acute MI STEMI definition STEMI treatment guidelines STREAM TRIAL - Time is muscle! Are patients with T2D at elevated CV risk? EMPA-REG Outcome Study Design EMPA-REG Outcome Results Safety and Tolerability Unmet Need Regional Data Is honeycombing in an HRCT, the sole detector of IPF? Safety and Tolerability Combined evidence from the TOMORROW and INPULSIS® trials How does Nintedanib benefit patients in preserving lung function? INSTAGE Trial Combined evidence from the TOMORROW and INPULSIS® trials How does dosing and administration of Nintedanib help compliance of IPF patients? Adverse Event Management Long-term Safety and Tolerability of Nintedanib in Patients with IPF Consider Jardiance for T2D patients with heart failure Long-term Safety and Tolerability of Nintedanib in Patients with IPF Lowest Renal Excretion Rate CVOTs CARMELINA: Time to first occurrence of adjudication-confirmed HHF Patients Achieving HbA1c World Kidney Day 2019 TRAJENTA Hypo and Weight Gain World Kidney Day 2019 TRAJENTA Hypo and Weight Gain Graham 2019 Article in Press BMS/DES SUBGROUP of RE-DUAL PCI RE-DUAL THE RENAL FUNCTION SUBGROUP Specified subanalysis of the RE-DUAL PCI trial TICAGRELOR / CLOPIDOGREL SUBGROUP Medicare Graham 2015 RWE RWE Lin 2015 RWE Nielsen 2017 RE-DUAL PCI RE-DUAL Vs Pioneer Infographic Efficacy Comparison RWE Comparison On Safety & Effectiveness Of Pradaxa VS Warfarin (Villines 2015) RWE Comparison On Safety & Effectiveness of Pradaxa VS Warfarin (Larsen 2016 ) RE-DUAL PCI 2018 EHRA Guidelines On Use of NOACs In Patients With AF RE-DUAL PCI Cannon NEJM 2017 RWE Hernandez 2017 Heidbuchel 2015 Europace (Updated European Heart Rhythm Association) 2016 ESC Guidelines in AF Quick Guide of SPAF RWE Bai 2017 RE-VERSE AD Study RWE Larsen 2016 Load more
